ANKENY, Iowa—Embria Health Sciences’ EpiCor dried fermentate can significantly reduce free radical formation under oxidative stress. (Journal of Medicinal Food, 2014 Aug; Online. doi:10.1089/jmf.2013.0158.)
The new research also shows pretreatment of PMN cells with EpiCor can reduce migration toward the inflammatory chemokine LTB4 (also known as chemotaxis), which was also statistically significant over a wide dose range.
“This human clinical trial can be thought of as a model using the outer epidermis (skin) to simulate how an oral dose of EpiCor might interact with the gut epithelium," stated Stuart Reeves, Ph.D., co-author of the study and director of research and development at Embria Health Sciences, for the in vivo part of the study. “The positive results are very promising, and complement the earlier published in vitro work showing gut health benefits."
“Investment in human clinical research is key to Embria’s leadership position," said Larry Robinson, co-author of the study and vice president of scientific affairs. “Through research, Embria continues to identify EpiCor’s multiple modes-of-action, further differentiating EpiCor from other immune ingredients."